

Resource Summary Report

Generated by NIF on Jul 31, 2026

PE anti-mouse CD98 (4F2)

RRID:AB_1186107

Type: Antibody

Proper Citation

BioLegend Cat# 128207, RRID:AB_1186107

Antibody Information

URL: http://antibodyregistry.org/AB_1186107

Proper Citation: BioLegend Cat# 128207, RRID:AB_1186107

Target Antigen: CD98

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD98 (4F2)

Description: This monoclonal targets CD98

Target Organism: mouse

Clone ID: Clone RL388

Antibody ID: AB_1186107

Vendor: BioLegend

Catalog Number: 128207

Alternative Catalog Numbers: 128208

Record Creation Time: 20250819T234457+0000

Record Last Update: 20250820T061747+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD98 (4F2).

No alerts have been found for PE anti-mouse CD98 (4F2).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kates M, et al. (2025) Protocol for halofuginone-mediated metabolic reprogramming of murine T cells via activation of the GCN2 pathway. STAR protocols, 6(4), 104173.

St Paul M, et al. (2024) Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy. Cell reports. Medicine, 5(3), 101465.

Chappaz S, et al. (2021) Homeostatic apoptosis prevents competition-induced atrophy in follicular B cells. Cell reports, 36(3), 109430.

Frost JN, et al. (2021) Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med (New York, N.Y.), 2(2), 164.

Chatterjee S, et al. (2018) CD38-NAD⁺Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell metabolism, 27(1), 85.

Wu J, et al. (2017) Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogeneic CD4⁺ T Cell Dysfunction. Immunity, 47(6), 1114.